^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | AVTX-006 (mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Excerpt:
We further evaluated the effects of intermittent dosing of OSI-027 in the PTEN null IGR-OV1 ovarian carcinoma xenograft model. OSI-027 administration at 50 mg/kg once daily for 14 days resulted in 100% TGI (Fig. 5E). OSI-027 administration at 150 mg/kg once every 3 days × 5 doses, corresponding to the same cumulative dose of 50 mg/kg per day, resulted in equivalent TGI (100% median TGI with 17% regression)...
DOI:
10.1158/1535-7163.MCT-10-1099
